ACE2 inhibition was reported as being unfavorable in COVID-19 patients due to the consequent decrease in the production of angiotensin 1–7, that possess anti-inflammatory, antifibrotic and vasodilatory actions via the Mas receptor [31]. The gene discussed is AGT; the disease is COVID-19.